Prognostic Value and Biological Function of Galectins in Malignant Glioma

Zhu, Hongtao; Liú, Dan; Cheng, Lidong; Liu, Jingdian; Wang, Guanghui; Li, Huan; Zhang, Yang; Mi, Hailong; Zhang, Suojun; Shu, Kai; Yu, Xingjiang

doi:10.3389/fonc.2022.834307

Cited by 7 publications

(7 citation statements)

References 36 publications

(42 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We demonstrated that LGALS1 is involved in immunosuppression, might be correlated with reduced survival in GBM patients, and that LGALS1 KO in GBM tumor cells can transform the immune landscape. Several research groups have reported similar findings (Baker et al, 2014;Barnes et al, 2018;Chou et al, 2018;Chen et al, 2019;Sharanek et al, 2021;Guda et al, 2022;Zhu et al, 2022). LGALS1 has been shown to drive resistance to chemo-and immunotherapy, and to be associated with poor survival.…”

Section: Discussionmentioning

confidence: 61%

Single‐cell profiling and zebrafish avatars reveal LGALS1 as immunomodulating target in glioblastoma

Finotto,

Cole,

Giese

et al. 2023

EMBO Mol Med

View full text Add to dashboard Cite

Glioblastoma (GBM) remains the most malignant primary brain tumor, with a median survival rarely exceeding 2 years. Tumor heterogeneity and an immunosuppressive microenvironment are key factors contributing to the poor response rates of current therapeutic approaches. GBM‐associated macrophages (GAMs) often exhibit immunosuppressive features that promote tumor progression. However, their dynamic interactions with GBM tumor cells remain poorly understood. Here, we used patient‐derived GBM stem cell cultures and combined single‐cell RNA sequencing of GAM‐GBM co‐cultures and real‐time in vivo monitoring of GAM‐GBM interactions in orthotopic zebrafish xenograft models to provide insight into the cellular, molecular, and spatial heterogeneity. Our analyses revealed substantial heterogeneity across GBM patients in GBM‐induced GAM polarization and the ability to attract and activate GAMs—features that correlated with patient survival. Differential gene expression analysis, immunohistochemistry on original tumor samples, and knock‐out experiments in zebrafish subsequently identified LGALS1 as a primary regulator of immunosuppression. Overall, our work highlights that GAM‐GBM interactions can be studied in a clinically relevant way using co‐cultures and avatar models, while offering new opportunities to identify promising immune‐modulating targets.

show abstract

Section: Discussionmentioning

confidence: 61%

Single‐cell profiling and zebrafish avatars reveal LGALS1 as immunomodulating target in glioblastoma

Finotto,

Cole,

Giese

et al. 2023

EMBO Mol Med

View full text Add to dashboard Cite

show abstract

“…Intriguingly, Gal-8 is expressed only in tumor prostate cells other than normal prostate tissue, implying its potential as a specific biomarker for prostate cancer [ 54 ]. Gal-8 has also been reported to involved in tumor cell proliferation, adhesion, migration and EMT in lung cancer, breast cancer, ovarian cancer, and malignant glioma [ 17 , 38 , 55 – 57 ]. Mechanically, Gal-8 regulates the adhesion and migration of lung cancer cells by binding to integrins and activates the downstream focal adhesion kinase (FAK) pathway [ 56 ], promoting breast cancer cell migration through interacting with activated leukocyte cell adhesion molecule such as CD166/ALCAM receptors [ 57 ].…”

Section: Introductionmentioning

confidence: 99%

“…In breast cancer and malignant melanoma, overexpression of cytoplasmic Gal-9 may inhibit tumor metastasis and attenuate recurrence [ 65 ]. More recently, Gal-9 indicates emerging potential as a therapeutic target for cancers, by serving as a good prognostic factor for kidney cancer and an independent indicator of poor prognosis in glioma [ 38 , 66 ]. Gal-9 also possesses immunomodulatory effects by serving as a ligand for T-cell immunoglobulin and mucin structural domain protein 3 (Tim-3), which are crucial for anticancer immunity [ 67 ].…”

Section: Introductionmentioning

confidence: 99%

Galectins and galectin-mediated autophagy regulation: new insights into targeted cancer therapy

Liú

Zhu

2023

Biomark Res

Self Cite

View full text Add to dashboard Cite

Galectins are animal lectins with specific affinity for galactosides via the conserved carbohydrate recognition domains. Increasing studies recently have identified critical roles of galectin family members in tumor progression. Abnormal expression of galectins contributes to the proliferation, metastasis, epithelial-mesenchymal transformation (EMT), immunosuppression, radio-resistance and chemoresistance in various cancers, which has attracted cumulative clinical interest in galectin-based cancer treatment. Galectin family members have been reported to participate in autophagy regulation under physiological conditions and in non-tumoral diseases, and implication of galectins in multiple processes of carcinogenesis also involves regulation of autophagy, however, the relationship between galectins, autophagy and cancer remains largely unclear. In this review, we introduce the structure and function of galectins at the molecular level, summarize their engagements in autophagy and cancer progression, and also highlight the regulation of autophagy by galectins in cancer as well as the therapeutic potentials of galectin and autophagy-based strategies. Elaborating on the mechanism of galectin-regulated autophagy in cancers will accelerate the exploitation of galectins-autophagy targeted therapies in treatment for cancer.

show abstract

“…Despite various therapies have emerged for GC patients, most of the patients' treatment still fail finally, which is due to drug resistance, tumor recurrence, and metastasis. 1 Cancer stem cells (CSCs) or cancer stemness has been considered to be one of the root of drug resistance, tumor metastasis, and occurrence. 2 Therefore, it is urgent to find new potential targets to deal with GC stemness.…”

Section: Introductionmentioning

confidence: 99%

“…Gastric cancer (GC) holds its high fatality rate and morbidity around the world. Despite various therapies have emerged for GC patients, most of the patients' treatment still fail finally, which is due to drug resistance, tumor recurrence, and metastasis 1 . Cancer stem cells (CSCs) or cancer stemness has been considered to be one of the root of drug resistance, tumor metastasis, and occurrence 2 .…”

Section: Introductionmentioning

confidence: 99%

CircRPPH1 promotes the stemness of gastric cancer cells by targeting miR‐375/SLC7A11 axis

Liu

Yang

Deng

et al. 2022

Environmental Toxicology

View full text Add to dashboard Cite

This study mainly focuses on revealing the role of circRPPH1 in gastric cancer cell stemness. In vitro and in vivo experiments were performed to evaluate the effects of circRPPH1 on gastric cancer cell stemness. Luciferase reporter and RIP assays were implemented to reveal the underlying mechanisms. MiR‐375 directly bound to circRPPH1 in gastric cancer cells. And circRPPH1 acted as an miR‐375 sponge to positively regulate SLC7A11 expression, which has been confirmed to be the direct target of miR‐375 in gastric cancer, and thus regulated ferroptosis. Moreover, circRPPH1 promoted the stemness of gastric cancer cells dependent on the miR‐375/SLC7A11. This study provides a potential target for gastric cancer progression based on the circRPPH1/miR‐375/SLC7A11 regulatory axis.

show abstract

Prognostic Value and Biological Function of Galectins in Malignant Glioma

Cited by 7 publications

References 36 publications

Single‐cell profiling and zebrafish avatars reveal LGALS1 as immunomodulating target in glioblastoma

Single‐cell profiling and zebrafish avatars reveal LGALS1 as immunomodulating target in glioblastoma

Galectins and galectin-mediated autophagy regulation: new insights into targeted cancer therapy

CircRPPH1 promotes the stemness of gastric cancer cells by targeting miR‐375/SLC7A11 axis

Contact Info

Product

Resources

About